[Heptral potentialities in the treatment of hepatic damage in children with malignant blood disease].
To assess benefit for children with malignant blood disease (MBD) of the hepatoprotector heptral. 67 children with blood malignancy aged 3-14 years were examined (53 of them had acute lymphoblastic leukemia). 39 patients were in the study group (25 of them had hepatitis B or C), 28 were controls. Initially, heptral was injected intravenously (14 days) then orally (16-30 days). Activity of transaminases and number of violations of polychemotherapy protocols because of hepatic toxicity were registered. Heptral administration led to inhibited activity of AlAT and AsAT especially in non-infected patients. Protocol deviations became less frequent. Heptral is a potent hepatoprotector in hepatic lesions of toxic, viral and mixed origin.